These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 23883936)
21. Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease. Kumar NT; Liestøl K; Løberg EM; Reims HM; Mæhlen J Virchows Arch; 2015 Aug; 467(2):225-35. PubMed ID: 25898889 [TBL] [Abstract][Full Text] [Related]
22. Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Li Z; Del-Aguila JL; Dube U; Budde J; Martinez R; Black K; Xiao Q; Cairns NJ; ; Dougherty JD; Lee JM; Morris JC; Bateman RJ; Karch CM; Cruchaga C; Harari O Genome Med; 2018 Jun; 10(1):43. PubMed ID: 29880032 [TBL] [Abstract][Full Text] [Related]
23. Integration of transcriptomic and genomic data suggests candidate mechanisms for APOE4-mediated pathogenic action in Alzheimer's disease. Caberlotto L; Marchetti L; Lauria M; Scotti M; Parolo S Sci Rep; 2016 Sep; 6():32583. PubMed ID: 27585646 [TBL] [Abstract][Full Text] [Related]
24. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques. Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353 [TBL] [Abstract][Full Text] [Related]
25. Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. Durazzo TC; Mattsson N; Weiner MW; Nicotine Tob Res; 2016 Feb; 18(2):204-11. PubMed ID: 25847292 [TBL] [Abstract][Full Text] [Related]
26. Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease? Chouinard-Watkins R; Plourde M Nutrients; 2014 Oct; 6(10):4452-71. PubMed ID: 25333200 [TBL] [Abstract][Full Text] [Related]
27. Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice. Carter AY; Letronne F; Fitz NF; Mounier A; Wolfe CM; Nam KN; Reeves VL; Kamboh H; Lefterov I; Koldamova R PLoS One; 2017; 12(2):e0172161. PubMed ID: 28241068 [TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. Hartman RE; Laurer H; Longhi L; Bales KR; Paul SM; McIntosh TK; Holtzman DM J Neurosci; 2002 Dec; 22(23):10083-7. PubMed ID: 12451108 [TBL] [Abstract][Full Text] [Related]
29. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk. Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998 [TBL] [Abstract][Full Text] [Related]
30. Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults. Luckett ES; Zielonka M; Kordjani A; Schaeverbeke J; Adamczuk K; De Meyer S; Van Laere K; Dupont P; Cleynen I; Vandenberghe R Alzheimers Res Ther; 2023 Jul; 15(1):121. PubMed ID: 37438770 [TBL] [Abstract][Full Text] [Related]
31. KIAA1462, a coronary artery disease associated gene, is a candidate gene for late onset Alzheimer disease in APOE carriers. Murdock DG; Bradford Y; Schnetz-Boutaud N; Mayo P; Allen MJ; D'Aoust LN; Liang X; Mitchell SL; Zuchner S; Small GW; Gilbert JR; Pericak-Vance MA; Haines JL PLoS One; 2013; 8(12):e82194. PubMed ID: 24349219 [TBL] [Abstract][Full Text] [Related]
32. Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer's disease. Shinohara M; Murray ME; Frank RD; Shinohara M; DeTure M; Yamazaki Y; Tachibana M; Atagi Y; Davis MD; Liu CC; Zhao N; Painter MM; Petersen RC; Fryer JD; Crook JE; Dickson DW; Bu G; Kanekiyo T Acta Neuropathol; 2016 Aug; 132(2):225-234. PubMed ID: 27179972 [TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein E phenotypes in healthy normal controls and demented subjects with Alzheimer's disease and vascular dementia in Mie Prefecture of Japan. Nakayama S; Kuzuhara S Psychiatry Clin Neurosci; 1999 Dec; 53(6):643-8. PubMed ID: 10687744 [TBL] [Abstract][Full Text] [Related]
34. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Darreh-Shori T; Modiri N; Blennow K; Baza S; Kamil C; Ahmed H; Andreasen N; Nordberg A Neurobiol Aging; 2011 Jul; 32(7):1236-48. PubMed ID: 19713000 [TBL] [Abstract][Full Text] [Related]
35. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Yu L; Boyle PA; Nag S; Leurgans S; Buchman AS; Wilson RS; Arvanitakis Z; Farfel JM; De Jager PL; Bennett DA; Schneider JA Neurobiol Aging; 2015 Nov; 36(11):2946-2953. PubMed ID: 26341746 [TBL] [Abstract][Full Text] [Related]
36. Alzheimer disease: Joining the dots between APOE ε4 and late-onset Alzheimer disease via integrative genomics. Kingwell K Nat Rev Neurol; 2013 Sep; 9(9):483. PubMed ID: 23938735 [No Abstract] [Full Text] [Related]
37. Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele. Pahnke J; Walker LC; Schroeder E; Vogelgesang S; Stausske D; Walther R; Warzok RW Acta Neuropathol; 2003 Jan; 105(1):25-9. PubMed ID: 12471457 [TBL] [Abstract][Full Text] [Related]